CN103533851A - Prebiotic carbohydrate compositions - Google Patents

Prebiotic carbohydrate compositions Download PDF

Info

Publication number
CN103533851A
CN103533851A CN201280009663.9A CN201280009663A CN103533851A CN 103533851 A CN103533851 A CN 103533851A CN 201280009663 A CN201280009663 A CN 201280009663A CN 103533851 A CN103533851 A CN 103533851A
Authority
CN
China
Prior art keywords
composition
application
glucan
galactooligosaccharide
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280009663.9A
Other languages
Chinese (zh)
Inventor
京特·萨瓦特兹奇
R·泽伦卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milk Co Of Germany
Original Assignee
Milk Co Of Germany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milk Co Of Germany filed Critical Milk Co Of Germany
Publication of CN103533851A publication Critical patent/CN103533851A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to use of a carbohydrate composition for production of a product with prebiotic action, the composition comprising, as carbohydrates, in addition to mono- and/or disaccharides, at least one galactooligosaccharide and at least one glucan having a base structure composed of alpha 1-4 and/or alpha 1-6 bonded glucose units.

Description

Prebiotics carbohydrate composition
The present invention relates to the composition of carbohydrate, described composition comprises galactooligosaccharide and basic structure is the glucan of the glucose unit of α 1-4 and/or α 1-6 bonding, and described composition is for the production of food or the medicine with prebiotic effect.
In food, the Main Function of carbohydrate is to provide energy for host organisms.But scientific research shows, some carbohydrates have the other function that can support some bioprocess.These materials are also used as the basic substance of functional food.The carbohydrate (so-called prebiotics) why Here it is has this type of prebiotic effect in recent years is more and more added into the reason of food and medicine.Term prebiotic effect has been described the impact that (particularly large intestine) bacterium is grown surely.
Therefore prebiotics is characterised in that they are not digested in small intestine, can not be absorbed, until their arrive large intestine, they are digested by some selective bacterium and its nutrition is provided there.But the microorganism that prebiotics material only has useful effect to those to host organisms in target mode provides support.
Now, suppose that gut flora is comprised of hundreds of bacteriums, wherein major part is present in large intestine.In this case, current only known a series of bacterium that can be detected outward at intestines.By such as modern methods based on DNA such as grand genome analysises, attempt detecting these bacteriums, it is seldom known wherein only having up to now.But, in laboratory, at present mainly with classical bacteriological method, carry out the growth of bacterial detection and from the inhibition of the pathogenic bacteria of fecal specimens.
Some prebiotics materials that belong to carbohydrate mainly in large intestine so-called Bifidobacterium and lactic acid bacteria (for example lactobacillus acidophilus (Lactobacillus acidophilus)) transform.Therefore, these bacteriums, particularly Bifidobacterium, grow sooner than other selective bacterium ground, and partly suppress the growth of other bacterium, particularly also partly suppresses the growth of pathogenic bacteria.This is called to short bifidobacterium growth effect (bifidogenic effect).As the result of Bifidobacterium dominance growth, the positive health effect to host organisms has been discussed, for example suppress disease and healthy and strong grow up (thriving) is improved.
The disease-resistant originality effect of prebiotics has been discussed conventionally; Comprising: time of staying shortening, cholesterol levels decline, the blood sugar of food in intestines responds reduction, bone health (calcium absorption) improvement, energy absorption minimizing, the improvement of chronic enteritis symptom and develops into the risk minimizing of intestinal cancer.
The effect relevant to health has been discussed, particularly infant nutrition aspect.Lacto is contained the relatively large carbohydrate with prebiotic effect, and described carbohydrate has various molecular composition (D.Newburg, Oligosaccharides in human milk and bacterial clonisation; JPGN30: 8-17 page (2000)).
In the manufacture of infant's food, in the past few years, the prebiotics carbohydrate admixture being comprised of FOS and the galactooligosaccharide of long-chain creates self on market.This mixture is disclosed in EP1105002.In described application, explicitly point out and get rid of carbohydrate/sugar (referring to for example [0040] section) that its glucose unit has α 1-4 and/or α 1-6 key.This restriction is based on the following fact: the obtainable carbohydrate with this structure was insoluble at that time.
In clinical trial widely, used the carbohydrate admixture described in EP1105002, and proved its short bifidobacterium growth effect (Moro G, Minoli I, Mosac M etc.: Dosage-related bifidogenic effects of galacto-and fructooligosaccharides in formula-fed term infants; J Pediatr Gastroenterol Nutr34:291-295 (2002)).
In the clinical research about baby, what can confirm is can also be by independent galactooligosaccharide (, do not add the FOS of long-chain) obtain and urge bifidobacterium growth effect (S.Fanaro, B.Marten.R.Bagna, V.Vigi, C.Fabris, L.Pena-Quintana, F.Arguelles, K.E.Scholz-Ahrens, G.Sawatzki, R.Zelenka, J.Schrezenmeir, M.de Vrese and E.Bertino:Galacto-oligosaccharides Are Bifidogenic And Safe at Weaning:A Double-blind Randomized Multicenter Study.JPGN 48:82-88, 2009).
But, more the FOS of long-chain does not prove the (Y.Bouhnik of short Bifidobacterium, L.Raskine, G.Simoneau etc.: The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans:double-blind, randomized, parallel-group, dose-response relation study; Am.J.Clin.Nutr.80:1658-64 (2004)).It is relevant to the interpolation of the FOS of long-chain that the change that only other bacterium grows surely seems.
In addition, shown that being particularly added in larger baby and adult of FOS causes slight flatulence.
Therefore, task of the present invention is to provide the composition of the prebiotic effect that demonstrates improvement.
Completely amazing and unforeseeable to those skilled in the art, basic structure is that the glucan of the glucose unit of α 1-4 and/or α 1-6 bonding can combine in fact better with galactooligosaccharide, for prebiotic compositions.In addition, since approximately 2002, this glucan can obtain with water-soluble form.
Therefore, the application that carbohydrate composition has in the product of prebiotic effect in preparation is theme of the present invention, described carbohydrate composition comprises at least one galactooligosaccharide and at least one glucan, and described glucan has the basic structure of the glucose unit of α 1-4 and/or α 1-6 bonding.Preferably, described glucan is soluble glucan in water.
According to the present invention, soluble saccharide is such carbohydrate, and it at room temperature forms uniform solution in physical significance in water, and concentration is at least 1g/L and (sees
Figure BDA00003692634700031
chemie Lexikon).
According to the present invention with according to the definition of application in the world, carbohydrate or the prebiotics with prebiotic effect are indigestible COF,, the nonabsorbable composition of small intestine of Healthy People, it optionally stimulates growth and/or the activity of the bacterial species of bacterial species or limited quantity, therefore host organisms is had to health promotion effect (Roberfroid, M.C.:Prebiotics:preferential substrates for specific germs? Am J Clin Nutr73/ supplementary issue): 406S-409S (2001)).
The invention is characterized in when by galactooligosaccharide and basic structure being the glucan of the glucose unit of α 1-4 and/or α 1-6 bonding while being used in combination, occurred working in coordination with significantly prebiotic effect.
The glucan that the present invention uses is compound sugar and/or the polysaccharide with at least 3 D-Glucose monomers, and these monomers interconnect by glycosidic bond (in this case by α-glycosidic bond).They can be included in carbohydrate composition respectively individually, or are included in carbohydrate composition with the form of the mixture of two or more glucans.Particularly preferred glucan is that dextran (has α-Isosorbide-5-Nitrae/1,2/1, α-1 of 3 side chains, 6-glucan), turn sugar chain coccus glucan (mutans, α-1,6-glucan), glycogen (α-1,4 and α-1,6-glucan), pulullan polysaccharide (α-Isosorbide-5-Nitrae and α-1,6-glucan) and starch (α-1,4 and α-1,6-glucan (amylose, amylopectin)).Particularly, described carbohydrate composition preferably comprises starch.
In particularly preferred embodiments, catabolite and/or resistance dextrosan that the glucan that the present invention uses occurs while being resistant starch, resistant starch degraded.As resistant starch, particularly preferably use resistant maltodextrin and/or resistant dextrin.
Resistant starch is that chemical composition is similar to the material of conventional starch and the product occurring when by starch degradation, and they are normally indigestible, that is, they are not degraded by human digestive enzyme.This means, resistant starch is not by the starch of the intestinal absorption of Healthy People and the product that occurs when by starch degradation, therefore can classify as fiber.
Resistant starch can be categorized into four kinds of hypotypes:
-1 type: the not obtainable starch of physical method (for example, from cereal and plant component)
-2 types: the natural granular starch of high-crystallinity (for example, from banana)
-3 types: the part high-crystallinity starch that (boiling) produces by bringing back to life (retrogradation) (gelatinization)
-4 types: converted starch
The positive role of the formation of the positive role of these so-called fibers, particularly SCFA being discussed and being caused, the described SCFA main metabolic end-product that corresponding bacterium produces in large intestine of serving as reasons.They are metabolin acetic acid esters (salt), propionic ester (salt) and butyrate (salt) (D.L.Topping and P.M.Clifton:Short-chain fatty acids and human colonic function:Roles of resistant starch and non-starch polysaccharides; Physiol.Rev.81:1031-1064 (2001)).Particularly to intestines function, (the particularly growth to enterocyte) has positive role to butyrate (salt), and reason is that it is mainly used as the energy substrate of host organisms.These aliphatic acid are essential for the cyclic regeneration of intestinal mucosa especially.The cell division of the butyrate producing in addition, (salt) inhibition cancer cell.The prebiotics carbohydrate that therefore, can produce this type of SCFA by gut flora has higher-value for host organisms.
The preparation example of resistant starch is as being described in WO2008/080630.In described document, can find molecular structure about resistant starch, about confirmation method be used alone as the out of Memory of prebiotics COF.
Do not limit under general principle, C*Actistar (being manufactured by Cerestar), Novelose, HI-MAIZE260 or HI-MAIZE1043 (by National Starch, being manufactured) are the typical products of the above resistant starch of existing market.
Recently, on market, also provide water-soluble resistant maltodextrin.They do not comprise conventionally with limiting, for example product Nutriose-FB and Nutriose-FM (by Roquette, manufactured, degree of polymerization DP is approximately >=10) and product F ibersol-2 (being manufactured by ADM/Matsutani).In addition, on market, also can obtain water-soluble resistant dextrin/dextrosan now.They comprise that product Litesse, Litesse-Two and Litesse-Ultra (being manufactured by Danisco) and product STA-LITE are (by Tate& Lyle manufactures) (degree of polymerization DP is approximately >=12).
The application of modification resistant starch in the gastral microorganism of improvement grows surely for example described in EP0910359.Therefore, the prebiotic effect of resistant starch itself is known.In WO2005/056023 for example, also having described carbohydrate and resistant starch group share and makes prebiotics and combination product thereof.But, the effective especially prebiotic effect while being before not yet described in the combination of the present invention of using galactooligosaccharide and resistant starch.
The aforementioned combination of prebiotics of the galactooligosaccharide in EP1105002 and FOS, in WO2006/134409, describe the combination of prebiotics of FOS and multiple other carbohydrate (for example common (non-resistance) starch and hydrolysate thereof, indigestion dextrosan, galactooligosaccharide and other material), wherein conventionally always must exist one or more FOSs as composition.
But in a preferred embodiment, according to carbohydrate composition of the present invention, do not comprise FOS.
If the carbohydrate that glucose unit in basic structure is connected with α 1-4 and/or α 1-6 key and galactooligosaccharide combination, surprisingly, realized short bifidobacterium growth effect in fact significantly, even if this means by add the composition of the present invention of less amount in food or medicine, also only can realize the substantially lower effect that can realize of independent each material (galactooligosaccharide or resistant starch/maltodextrin/dextrin) of higher concentration.
In addition, contrary with the combination of galactooligosaccharide and FOS, at the study subject with composition of the present invention (that is, the combination of galactooligosaccharide and resistant starch and/or dextrosan) treatment, particularly, in baby, can observe flatulence degree and significantly reduce.
In this case, dextrosan most probable is stimulation of bifidobacteria specifically, rather than lactobacillus (H.M.Probert, J.H.A.Apajalahti, N.Rautonen, J.Stowell and G.R.Gibson:Polydextrose, lactitol, and fructo-oligosaccharide fermentation by colonic bacteria in a three-stage continuous culture system; Appl.Environ.Microbiol.70:4505-4511 (2004)), and in target mode suppress bacteroid (bacteroid) species.
Galactooligosaccharide of the present invention be water miscible, there are 3～9 monosaccharide units, preferably there is the compound sugar carbohydrate of 3～6 monosaccharide units, be mainly wherein galactolipin particularly D-galactolipin as monose, exist.Therefore, the galactooligosaccharide compound sugar of three, four, five or six sugar preferably.They can be included in carbohydrate composition separately individually, or are included in carbohydrate composition with the form of the mixture of two or more galactooligosaccharides.Especially preferably use alpha-galactooligosaccharide or β-galactooligosaccharide.Particularly, preferably use β-galactooligosaccharide.
In commercial scale, with beta galactosidase, by the so-called glucosides that turns, react to produce galactooligosaccharide (also referred to as GOS).Therefore, conventionally also referred to as turning galactooligosaccharide (trans-galactooligosaccharides) (TOS, TGOS).Do not limit under general principle, the galactooligosaccharide that the present invention uses for example has following molecular structure:
Alpha-D-glucose-(1-4)-β-D-galactolipin [(1-6)-β-D-galactolipin] n, n=1～4 wherein
By the obtainable product Oligomate of trade (Yakult) and Vivinal-GOS (DOMO/Frieslandfoods), it is the example of galactooligosaccharide of the present invention.
The glucan of the α 1-4 of the galactooligosaccharide that the preferred mixture of prebiotics carbohydrate composition of the present invention comprises 50% weight～95% weight and 5% weight～50% weight and/or α 1-6 bonding.The composition of the glucan of the glucose unit with α 1-4 and/or α 1-6 bonding of the galactooligosaccharide of 80% weight～90% weight and 20% weight～10% weight particularly preferably.
The carbohydrate that also modified monomer can be used for the present invention.For example, can carry out enzymatic modification to described galactooligosaccharide or described glucan.As selection, can also carry out technology modification.In addition, monomer or the unit that forms it also can by-OSO3H and/or-OPO 3h is group modified.
In 240 babies at 6～8 monthly ages, the concentration of 4g/L of usining has been tested the galactooligosaccharide (Vivinal-GOS by 80% weight comparing with the resistant maltodextrin of 100% galactooligosaccharide as infant formula product (infant formula) composition or 100% in clinical research, the composition of the present invention that the resistant maltodextrin (Nutriose-FM, Roquette) of DOMO/Frieslandfoods) and 20% weight forms.Result (logarithm value of the bacterial number in every gram of ight soil) about the confirmation amount of bacterium is shown in following table:
GOS＝Vivinal-GOS，DOMO/Frieslandfoods；rMD＝Nutriose-FM，Roquette
Surprisingly, clinical trial discloses, and in pablum, the combination of composition-galactooligosaccharide of the present invention and resistant maltodextrin and the independent carbohydrate of each equivalent are compared, and the bacterium in infant faeces is formed and obviously has more significant effect.Even if each independent amount of substance doubles, they can not reach the effect with composition of the present invention.
Composition of the present invention can be included in following product:
For preemie with for thering is the baby's of normal type pablum, for baby and children's food, clinical food, medicine and health food.In this case, composition of the present invention can be a part or the alternative conventional ingredient of these products.In this way, the carbohydrate particularly having existed can partly be substituted or supplement with described composition by described composition.For example, the main carbohydrate-lactose in infant formula product-can partly be substituted by mixture of the present invention.
The amount of the composition that the present invention is used be adjusted into age and concrete every day amount and with the function of medicament forms used.For example, at simple food supplement, for child's infant formula product and the follow-up formulation product of baby (follow-on formula), give the composition of the present invention of 3g～20g every day.It is the composition of the present invention of 2g～50g that adult can be contained ration every day (daily ration) with product.It can be the composition in food, health food, food supplement, clinical food and medicine.Composition of the present invention can also provide with the combination of liquid and solid form with other composition, as powder, as spray-dried powders, as emulsion, as compressed pills or with the form of capsule.
Below can at length explain composition constructed in accordance application in different product by means of corresponding exemplary formulation (being all powder-product).In this case, for exemplary food, each list meeting of the composition comprising and material is listed with form.
According to the method for well known to a person skilled in the art, manufacture each composition, for example water-based mutually in the dry and dry mixed that may need of mixing, homogeneity, pasteurization, spraying, and the additional option that makes powder cohesion.
By reference to whole disclosures of all applications, patents and publications of mentioning are above and below incorporated to the application.
Even without further explanation, suppose that those skilled in the art can farthest utilize above description.Cause and it should be understood that preferred embodiment and embodiment are only descriptive, and be never restriction disclosure.
Embodiment
1. infant formula product
The preparation of narrating is the basis of so-called infant formula product (that is the food that, can provide from birth for full-term newborn infant).
Figure BDA00003692634700071
Figure BDA00003692634700081
By selecting aforementioned component, prepared the food with following contained material.
Figure BDA00003692634700082
Figure BDA00003692634700091
2. the follow-up formulation product of baby
The preparation of narrating is the basis of so-called follow-up 2 sections of milk (follow-on milk2) (can think the food that the full-term newborn infant after 6 months provides).
Component in every 100g powder ? ?
Skimmed milk 180 g
Demineralized whey powder 31.5 g
Draft oil 23.1 g
Starch 15.4 g
Galactooligosaccharide syrup 8.8 g
Lactose 2.4 g
Dextrose syrup 1.2 g
Resistant maltodextrin 1.1 g
Emulsifying agent: soybean lecithin 655 mg
Calcium carbonate 560 mg
Potassium chloride 250 mg
Natrium citricum 220 mg
Tricalcium orthophosphate 190 mg
Potassium citrate 110 mg
Vitamin C 93 mg
L-Phe 51 mg
Magnesium carbonate 47 mg
L-Trp 29 mg
Taurine 27 mg
Ferric lactate 24 mg
Zinc oxide 5.1 mg
Nicotinic acid 4.9 mg
Pantothenic acid 1.6 mg
Vitamin E 1.4 mg
Copper sulphate 700 μg
Vitamin A 605 μg
Vitamin B1 565 μg
Zinc sulfate 510 μg
Pyridoxamine 485 μg
Vitamin B2 160 μg
Potassiumiodate 130 μg
Manganese sulfate 86 μg
Folic acid 72 μg
Vitamin K1 46 μg
Sodium selenate 30 μg
Biotin 12 μg
Neo dohyfral D3 9.5 μg
Cobalamin 054 μg
By selecting aforementioned component, prepared the food with following contained material.
Figure BDA00003692634700101
Figure BDA00003692634700111
Figure BDA00003692634700121
3. rehabilitation food (healing food)
Rehabilitation food is for example, for suffering from sick child, children and the adult's of enteron aisle abnormal (, diarrhoea) food.Following preparation marks for the rehabilitation food that can use with liquid form.
Component Amount (approximately) Unit
Skimmed milk 185 g
Banana powder 15.3 g
Dextrose syrup 14.2 g
Vegetable oil 13.8 g
Starch 13.0 g
Maltodextrin 9.7 g
Galactooligosaccharide syrup 8.7 g
Lactoprotein 5.9 g
Pre-gelatinized rice powder 3.0 g
Resistant maltodextrin 1.1 g
Natrium citricum 335 mg
Calcium carbonate 250 mg
CYSTINE 90 mg
Sodium chloride 75 mg
Vitamin C 56 mg
Magnesium carbonate 49 mg
Ferric pyrophosphate (iron diphosphate) 19 mg
Inositol 16 mg
Nicotinic acid 6.2 mg
Potassium citrate 47 mg
Vitamin E 3.4 mg
Zinc oxide 3.0 mg
Pantothenic acid 2.1 mg
Copper sulphate 640 μg
Vitamin B2 590 μg
Vitamin A 545 μg
Vitamin B1 510 μg
Pyridoxamine 440 μg
Potassiumiodate 135 μg
Folic acid 48 μg
Vitamin K1 42 μg
Sodium molybdate 27 μg
Biotin 11 μg
Neo dohyfral D3 8.5 μg
Sodium selenate 1.9 μg
Cobalamin 049 μg
By selecting aforementioned component, prepared the food with following contained material.
Figure BDA00003692634700131
Figure BDA00003692634700141

Claims (11)

1. carbohydrate composition has the application in the product of prebiotic effect in preparation, except monose and/or disaccharides, described composition comprises at least one galactooligosaccharide and at least one glucan as carbohydrate, and described glucan has the basic structure of the glucose unit of α 1-4 and/or α 1-6 bonding.
2. the application of composition as claimed in claim 1, is characterized in that, described glucan has water-soluble.
3. the application of composition as claimed in claim 1 or 2, is characterized in that, catabolite and/or resistance dextrosan that described glucan occurs while being resistant starch, resistant starch degraded.
4. the application of composition as claimed in claim 3, is characterized in that, described resistant starch is resistant maltodextrin and/or resistant dextrin.
5. the application of the composition as described in any one in claim 1～4, is characterized in that, described composition does not comprise any FOS.
6. the application of the composition as described in any one in claim 1～5, is characterized in that, described composition does not comprise any other compound sugar.
7. the application of the composition as described in any one in claim 1～6, is characterized in that, the glucan of the galactooligosaccharide that described composition comprises 50% weight～95% weight and 5% weight～50% weight.
8. the application of composition as claimed in claim 7, is characterized in that, the glucan of the galactooligosaccharide that described composition comprises 80% weight～90% weight and 10% weight～20% weight.
9. the application of the composition as described in any one in claim 1～8, is characterized in that, described composition also comprises one or more and is selected from the composition in the group that comprises protein, fat, carbohydrate, mineral matter, trace element and vitamin.
10. the application of the composition as described in any one in claim 1～9, is characterized in that, described product is food or medicine.
The application of 11. compositions as claimed in claim 10, is characterized in that, described food is infant formula product.
CN201280009663.9A 2011-02-25 2012-02-14 Prebiotic carbohydrate compositions Pending CN103533851A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011012494A DE102011012494A1 (en) 2011-02-25 2011-02-25 Prebiotic carbohydrate compositions
DE102011012494.2 2011-02-25
PCT/EP2012/052474 WO2012113677A1 (en) 2011-02-25 2012-02-14 Prebiotic carbohydrate compositions

Publications (1)

Publication Number Publication Date
CN103533851A true CN103533851A (en) 2014-01-22

Family

ID=45878904

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280009663.9A Pending CN103533851A (en) 2011-02-25 2012-02-14 Prebiotic carbohydrate compositions

Country Status (6)

Country Link
EP (1) EP2699109A1 (en)
CN (1) CN103533851A (en)
DE (1) DE102011012494A1 (en)
EA (1) EA201391205A1 (en)
UA (1) UA109930C2 (en)
WO (1) WO2012113677A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103609748A (en) * 2013-12-10 2014-03-05 内蒙古伊利实业集团股份有限公司 Hypoglycaemic milk powder for pregnant women and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481682A1 (en) * 1998-12-09 2004-12-01 N.V. Nutricia Preparation that contains oligosaccharides and probiotics
WO2007098593A1 (en) * 2006-03-03 2007-09-07 Health Beverage, Llc Fiber containing alkaline beverage and methods for production thereof
CN101453913A (en) * 2006-02-13 2009-06-10 斯维特韦尔有限公司 Functional sugar replacement
WO2010048481A1 (en) * 2008-10-24 2010-04-29 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US20100284980A1 (en) * 2009-05-11 2010-11-11 Rosales Francisco J Nutritional Composition To Promote Healthy Development And Growth
US20100316619A1 (en) * 2009-02-12 2010-12-16 Anja Wittke Nutritional composition with prebiotic component
CN101938915A (en) * 2007-12-10 2011-01-05 荷兰纽迪希亚公司 Paediatric fibre mixture

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN880996A0 (en) 1996-03-20 1996-04-18 Arnott's Biscuits Limited Selection and/or enhancement of resident microorganisms in the gastrointestinal tract
DE19836339B4 (en) 1998-08-11 2011-12-22 N.V. Nutricia carbohydrate mix
NO320546B1 (en) 2003-12-12 2005-12-19 Nova Biotics As Prebiotic combination products
HUP0500582A1 (en) 2005-06-13 2007-08-28 Csaba Jozsef Dr Jaszberenyi Foods food-additives and nutriment supplements or feed-additives with synergetic physiological effect
WO2007004883A2 (en) * 2005-07-05 2007-01-11 N.V. Nutricia A carbohydrate fraction and use thereof for a flat postprandial glucose response
BRPI0708701A2 (en) * 2006-03-10 2011-06-07 Nutricia Nv use of a non-digestible water-soluble saccharide
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
AR064557A1 (en) 2006-12-29 2009-04-08 Bayer Cropscience Ag CORN STAMP AND CORN FLOURS AND FOODS UNDERSTANDING THIS CORN CORN
US20090118227A1 (en) * 2007-11-07 2009-05-07 Bristol-Myers Squibb Company Carotenoid-containing compositions and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481682A1 (en) * 1998-12-09 2004-12-01 N.V. Nutricia Preparation that contains oligosaccharides and probiotics
CN101453913A (en) * 2006-02-13 2009-06-10 斯维特韦尔有限公司 Functional sugar replacement
WO2007098593A1 (en) * 2006-03-03 2007-09-07 Health Beverage, Llc Fiber containing alkaline beverage and methods for production thereof
CN101938915A (en) * 2007-12-10 2011-01-05 荷兰纽迪希亚公司 Paediatric fibre mixture
WO2010048481A1 (en) * 2008-10-24 2010-04-29 Mead Johnson Nutrition Company Nutritional composition to promote healthy development and growth
US20100316619A1 (en) * 2009-02-12 2010-12-16 Anja Wittke Nutritional composition with prebiotic component
US20100284980A1 (en) * 2009-05-11 2010-11-11 Rosales Francisco J Nutritional Composition To Promote Healthy Development And Growth

Also Published As

Publication number Publication date
EA201391205A1 (en) 2014-02-28
EP2699109A1 (en) 2014-02-26
DE102011012494A1 (en) 2012-08-30
WO2012113677A1 (en) 2012-08-30
UA109930C2 (en) 2015-10-26

Similar Documents

Publication Publication Date Title
US20220354876A1 (en) Human milk oligosaccharides to promote growth of beneficial bacteria
DE60128395T3 (en) NUTRITIONAL COMPOSITION WITH HEALTH PROMOTION, INCLUDING OLIGOSACCHARIDE
AU2011340881B2 (en) Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
Topping et al. Resistant starch as a prebiotic and synbiotic: state of the art
AU2011333861B2 (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CN101330838B (en) Method for preventing diseases in infants delivered via caesarean section
CA2822660C (en) Synbiotic combination of probiotic and human milk oligosaccharides
PT1871400E (en) Uronic acid and probiotics
Kim et al. Supplementation of infant formula with native inulin has a prebiotic effect in formula-fed babies.
CN105639631A (en) Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
AU2022203298A1 (en) Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rota virus-associated diarrhoea
DE60022513T2 (en) USE OF FATTY ACID DERIVATES IN NASAL GASTRALE ENTERAL FORMULATIONS
US20120107449A1 (en) Mineral-absorption promoter, food and feed
CN112741334B (en) Prebiotic compositions, and uses thereof
CN103533851A (en) Prebiotic carbohydrate compositions
Pant et al. Horticultural crops as a source of prebiotics
Bouckaert Infants, Prebiotics, and Digestive Health

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140122